Prostate cancer epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(→Race) |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}}; {{AE}} {{Rim}} {{sali}} | {{CMG}}; {{AE}} {{Rim}} {{sali}} | ||
{{Prostate cancer}} | {{Prostate cancer}} | ||
| Line 33: | Line 34: | ||
{| style="cellpadding=0; cellspacing= 0; width: 400px;" | {| style="cellpadding=0; cellspacing= 0; width: 400px;" | ||
|- | |- | ||
|style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''All Races''' ||style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''White''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Black''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Asian/Pacific Islander''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Hispanic''' | | style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" | || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''All Races''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''White''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Black''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Asian/Pacific Islander''' || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Hispanic''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align=center |'''Age-adjusted prevalence'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | 1690 per 100,000 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |1680 per 100,000 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left | 2610 per 100,000 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |870 per 100,000 ||style="font-size: 100; padding: 0 5px; background: #B8B8B8" align=left |1320 per 100,000 | | style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''Age-adjusted prevalence'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | 1690 per 100,000 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |1680 per 100,000 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | 2610 per 100,000 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |870 per 100,000 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |1320 per 100,000 | ||
|} | |} | ||
* Shown below is an image depicting the [[incidence]] of prostate cancer by race in the United States between 1975 and 2011.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | * Shown below is an image depicting the [[incidence]] of prostate cancer by race in the United States between 1975 and 2011.<ref name="SEER">Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.</ref> | ||
[[File:Incidence of prostate cancer.jpg|center|thumb|792x792px]] | |||
[[Image:Incidence of prostae cancer per race in USA.PNG|Incidence of prostate cancer per race in USA]] | [[Image:Incidence of prostae cancer per race in USA.PNG|Incidence of prostate cancer per race in USA]] | ||
Revision as of 17:03, 20 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2] Syed Musadiq Ali M.B.B.S.[3]
|
Prostate cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Prostate cancer epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Prostate cancer epidemiology and demographics |
|
Risk calculators and risk factors for Prostate cancer epidemiology and demographics |
Overview
The number of new cases of prostate cancer was 112.6 per 100,000 men per year. In 2018, there are expected to be approximately 165,000 new prostate cancer diagnoses and approximately 29,000 prostate cancer deaths. The number of deaths was 19.5 per 100,000 men per year. These rates are age-adjusted and based on 2011-2015 cases and deaths. Approximately 11.2 percent of men will be diagnosed with prostate cancer at some point during their lifetime, based on 2013-2015 data. In 2015, there were an estimated 3,120,176 men living with prostate cancer in the United States.
Epidemiology and Demographics
Prevalence
- In 2015, there were an estimated 3,120,176 men living with prostate cancer in the United States.[1]
- Rates of prostate cancer vary widely across the world. Although the rates vary widely between countries, it is least common in South and East Asia, more common in Europe, and most common in the United States.[2]
Incidence
- In 2018, there are expected to be approximately 165,000 new prostate cancer diagnoses and approximately 29,000 prostate cancer deaths[3].
- Prostate cancer is second only to non-melanoma skin cancer and lung cancer as the leading cause of cancer and cancer death, respectively, in United States men.
- Worldwide, there are an estimated 1,600,000 new cases of prostate cancer and 366,000 prostate cancer deaths annually, making it the most commonly diagnosed cancer in men and the seventh leading cause of male cancer death[4].
Age
- The incidence of prostate cancer increases with age; the median age at diagnosis is 66 years.
- While the overall age-adjusted incidence of prostate cancer in the United States between 2007 and 2011 is 147.6 per 100,000, the age-adjusted incidence of prostate cancer by age category is:[5]
- Under 65 years: 57.8 per 100,000
- 65 and over: 768.2 per 100,000
- Shown below is an image depicting the incidence of prostate cancer by age and race in the United States between 1975 and 2011.[5]
Race
- It usually affects individuals of the African American race. Asian, Hispanic and White individuals are less likely to develop prostate cancer.
- Shown below is a table depicting the age-adjusted prevalence of prostate cancer by race in 2011 in the United States.[5]
| All Races | White | Black | Asian/Pacific Islander | Hispanic | |
| Age-adjusted prevalence | 1690 per 100,000 | 1680 per 100,000 | 2610 per 100,000 | 870 per 100,000 | 1320 per 100,000 |
- Shown below is an image depicting the incidence of prostate cancer by race in the United States between 1975 and 2011.[5]
API: Asian/Pacific Islander; AI/AN: American Indian/ Alaska Native
References
- ↑ "Prostate Cancer - Cancer Stat Facts".
- ↑ "IARC Worldwide Cancer Incidence Statistics—Prostate". JNCI Cancer Spectrum. Oxford University Press. December 19, 2001. Retrieved on 2007-04-05 through the Internet Archive
- ↑ Siegel RL, Miller KD, Jemal A (January 2018). "Cancer statistics, 2018". CA Cancer J Clin. 68 (1): 7–30. doi:10.3322/caac.21442. PMID 29313949.
- ↑ Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabé E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castañeda-Orjuela C, Catalá-López F, Chiang P, Chibueze C, Chitheer A, Choi JY, Cowie B, Damtew S, das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer F, G/Hiwot TT, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Husseini A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Jee SH, Kasaeian A, Kedir MS, Khader YS, Khang YH, Kim D, Leigh J, Linn S, Lunevicius R, El Razek H, Malekzadeh R, Malta DC, Marcenes W, Markos D, Melaku YA, Meles KG, Mendoza W, Mengiste DT, Meretoja TJ, Miller TR, Mohammad KA, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo FA, Oladimeji KE, Oren E, Pa M, Park EK, Pereira DM, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana SM, Søreide K, Satpathy M, Sawhney M, Sepanlou SG, Shaikh MA, She J, Shiue I, Shore HR, Shrime MG, So S, Soneji S, Stathopoulou V, Stroumpoulis K, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tessema GA, Thakur JS, Tran BX, Ukwaja KN, Uzochukwu B, Vlassov VV, Weiderpass E, Wubshet Terefe M, Yebyo HG, Yimam HH, Yonemoto N, Younis MZ, Yu C, Zaidi Z, Zaki M, Zenebe ZM, Murray C, Naghavi M (April 2017). "Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study". JAMA Oncol. 3 (4): 524–548. doi:10.1001/jamaoncol.2016.5688. PMID 27918777. Vancouver style error: non-Latin character (help)
- ↑ 5.0 5.1 5.2 5.3 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.